Compare Manulife Financial Corporation (MFC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Sana Biotechnology Inc — how do they compare? Manulife Financial Corporation trades at $42.43 (market cap $69.48B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Manulife Financial Corporation is far larger — about 83× Sana Biotechnology Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Sana Biotechnology Inc for 23 Days on average.
| MFC | SANA | |
|---|---|---|
Market Cap | $69.48B | $836.71M |
Volume | 1,347,508 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $44.77 | $5.92 |
52-Week Low | $31.64 | $2.68 |
Typical Hold Time | 119 Days | 23 Days |
Enterprise Value | $64.75B | $749.96M |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.12, up 1.08% today, with a bearish technical signal from moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7%, while Q2 2026 earnings beat expectations. Analyst consensus is bullish with 57% buy ratings, though the consensus price target of $34.24 is below the current price. Recent news includes a new $750M subordinated notes offering and executive appointments.
Outlook is mixed: strong fundamentals and institutional interest support upside, but technical weakness and a high valuation relative to the price target pose risks. Key catalysts include Q3 2026 earnings and execution of growth initiatives in Asia.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
